Re-Inventing Infectious Disease: Antibiotic Resistance and Drug Development at the Bayer Company 1945-80

Medical History

Volumn 60, Issue 2, 2016, Pages 155-180

  Gradmann, Christoph ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

Antibiotic resistance; Bayer company; Drug development; Infectious disease; Staphylococcal infections; Tuberculosis

Indexed keywords

ANTIINFECTIVE AGENT; CLOTRIMAZOLE; STREPTOMYCIN;

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTIONS; DRUG DEVELOPMENT; DRUG INDUSTRY; GERMANY; HISTORY; HUMAN; MARKETING; MEDICAL RESEARCH; MYCOSES;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; BACTERIAL INFECTIONS; BIOMEDICAL RESEARCH; CLOTRIMAZOLE; DRUG DISCOVERY; DRUG INDUSTRY; DRUG RESISTANCE, MICROBIAL; GERMANY; HISTORY, 20TH CENTURY; HUMANS; MARKETING; MYCOSES; STREPTOMYCIN;

EID: 84938656306     PISSN: 00257273     EISSN: 20488343     Source Type: Journal    
DOI: 10.1017/mdh.2016.2     Document Type: Conference Paper

References (80)

1. Daniel E. Koshland, 'The Microbial Wars', Science, 257, (1992), 1021.
2. Graham A.J. Ayliffe and Mary P. English, Hospital Infection From Miasmas to MRSA (Cambridge: Cambridge University Press, 2003), 134-70
3. Mitchell L. Cohen, 'Epidemiology of Drug Resistance: Implications for a Post-Antimicrobial Era', Science, 257 (1992), 1050-5.
4. L.A. Reyolds and E.M. Tansey (eds), Superbugs and Superdrugs: A History of MRSA, (London:Wellcome Trust Centre for the History of Medicine at UCL 2008)
5. Robert Bud, Penicillin: Triumph and Tragedy (Oxford: Oxford University Press, 2007)
6. Nicholas B. King, 'The Scale Politics of Emerging Diseases', Osiris, 19, (2004), 62-76
7. David Satcher, 'Emerging Infections: Getting Ahead of the Curve', Emerging Infectious Diseases, 1, (1995), 6
8. Joshua Lederberg, Robert E. Shope and Stanley C. Oaks (eds), Emerging Infections. Microbial Threats to Health in the United States (Washington, DC: National Academic Press, 1992).
9. Michel Tibayrenc, 'The Golden Age of Genetics and the Dark Age of Infectious Diseases', Infection, Genetics and Evolution, 1 (2001), 1-2.
10. William C. Summers, 'Microbial drug resistance: a historical perspective', in R.G. Wax et al. (eds), Bacterial Resistance to Antimicrobials (Boca Raton, FL: CRC Press, 2008), 1-9
11. Frank Ryan, The Forgotten Plague: How the Battle Against Tuberculosis Was Won-and Lost (Boston: Little, Brown, 1993)
12. Claudia Eberhardt-Metzger and Renate Ries, Verkannt und heimtükisch-Die ungebrochene Macht der Seuchen (Basel: Birkhäuser, 1996)
13. H. Schadewaldt (ed.) Die Rückkehr der Seuchen (Köln: vgs, 1994).
14. Frank Macfarlane Burnet, The Natural History of Infectious Disease (Cambridge: Cambridge University Press, 1953), 1940 ix.
15. Kai F. Hünemörder, 'Kassandra im modernen Gewand. Die umweltapokalyptischen Mahnrufe der frühen 1970er Jahre', in F. Uekötter and J. Hohensee (eds), Wird Kassandra heiser? Die Geschichte falscher Ökoalarme (Stuttgart: Steiner, 2004), 78-97.
16. David Greenwood, Antimicrobial Drugs. Chronicle of a Twentieth Century Triumph (Oxford: Oxford University Press, 2008) 262-3.
17. Humphrey P. Rang, 'The development of the pharmaceutical industry', in H.P. Rang (ed.), Drug Discovery and Development: Technology in Transition (London: Churchill Livingstone, 2005), 3-18, here 16/7
18. Brad Spellberg et al., 'Trends in Antimicrobial Drug Development: Implications for the Future', Clinical Infectious Diseases, 38, (2004), 1279-86.
19. Cf. Maryn McKenna's blog on the empty pipeline: http://www.super bugtheblog.com/2009/11/antibiotics-eu-pipeline-is-empty-too.html.
20. See Maryn McKenna, Suberbug: The Fatal Menace of MRSA (New York: Free Press, 2010), ch. 12 on the end of antibiotics.
21. Author's transcription from http://www.youtube.com/watch?v=uZt6q2uwM2g.
22. Christian Bonah et al., 'Standard drugs and drug standards. A comparative historical study of pharmaceuticals in the 20th-century', in C. Bonah et al. (ed.), Harmonizing Drugs. Standards in 20th-Century Pharmaceutical History (Paris: Editions Glyphe, 2009), 17-27.
23. Gottfried Plumpe, Die I.G. Farbenindustrie AG: Wirtschaft, Technik und Politik 1904-45 (Berlin: Dunker & Humblodt, 1990).
24. Wolfgang Wimmer, 'Wir haben fast immer was Neues': Gesundheitswesen und Innovation der Pharma-Industrie in Deutschland 1880-935 (Berlin: Duncker & Humblodt, 1994).
25. Lutz Sauerteig, 'Ethische Richtlinien, Patientenrechte und ärztliches Verhalten bei der Arzneimittelerprobung 1892-31', Medizinhistorisches Journal, 35, (2000), 303-34
26. Axel Cäsar Hüntelmann, Paul Ehrlich: Leben, Forschung, Ö konomien, Netzwerke (Göttingen: Wallstein, 2011).
27. Christoph Gradmann, Laboratory Disease: Robert Koch's Medical Bacteriology (Baltimore, MD: Johns Hopkins University Press, 2009), 213-25.
28. Christoph Gradmann, 'Magic Bullets and Moving Targets: Antibiotic Resistance and Experimental Chemotherapy 1900-40', Dynamis, 31, (2011), 305-21.
29. Cay-Rüdiger Prüll, Andreas-Holger Maehle and Robert Francis Halliwell, A Short History of the Drug Receptor Concept (Basingstoke: Palgrave, 2009)
30. John Parascandola, 'The Theoretical Basis of Paul Ehrlich's Chemotherapy', Journal for the History of Medicine and Allied Sciences, 36, (1981), 19-43
31. Arthur Silverstein, Paul Ehrlich's Receptor Immunology: The Magnificent Obsession (San Diego, CA: Academic Press, 2003).
32. Horst Bernd Dünschede, Tropenmedizinische Forschung bei Bayer (Düsseldorf: Trilsch, 1971).
33. Bayer Leverkusen Tropenabteilung, Die Chemotherapie der Schlafkrankheit (Leverkusen: Bayer, 1938).
34. John E. Lesch, The First Miracle Drugs: How the Sulfa Drugs Transformed Medicine (Oxford: Oxford University Press, 2007)
35. Axel A.H. Dalhoff, 'Discovery and Development of Anti-infectives at Bayer: A Personal View. Part I: Antiparasitics, Sulfonamides, and Antitubercular drugs', Sim News, 57, (2007), 135-50, here 135-42.
36. Wilhelm Bartmann, Zwischen Tradition und Fortschritt. Aus der Geschichte der Pharmabereiche von Bayer, Hoechst und Schering von 1935-75 (Stuttgart: Steiner, 2003), 106-12.
37. John E. Lesch, 'Chemistry and biomedicine in an industrial setting: the invention of the sulfa drugs', in S.H. Mauskopf (ed.), Chemical Sciences in the Modern World (Philadelphia, PA, University of Pennsylvania Press, 1993), 158-215.
38. Hermann A. Baum, Geschichte der Pharma nach dem Zweiten Weltkrieg (Leverkusen: Bayer AG Leverkusen, 1983).
39. Jean-Paul Gaudillière and Ulrike Thoms, 'Pharmaceutical Firms and the Construction of Drug Markets: from Branding to Scientific Marketing', History and Technology, 29, (2013), 105-15
40. Ulrike Thoms, 'Standardizing Selling. Pharmaceutical marketing, the Pharmaceutical Company and the Marketing Expert (1900-80)', History and Technology, 29, (2013), 169-87.
41. Silvia Berger, Bakterien in Krieg und Frieden: eine Geschichte der medizinischen Bakteriologie in Deutschland 1890-933 (Göttingen: Wallstein, 2009), 27-90.
42. Axel A.H. Dalhoff, 'Discovery and Development of Anti-infectives at Bayer: A Personal View. Part II: ß-lactam antibiotics', Sim News, 58, (2008), 6-18
43. Heiko Braun, 'Von der Vertriebsund "Propagandapolitik" zum Pharmamarketing? Eine Marketinggeschichte des deutschen Pharmabereichs der Farbenfrabriken Bayer AG 1957-71' (Unpublished M.A. thesis: University of Bonn, 2009).
44. Charles-Edward Emory Winslow, The Conquest of Epidemic Disease: A Chapter in the History of Ideas (Princeton, NJ: Princeton University Press, 1987 (1967)).
45. John A. Kolmer, Penicillin Therapy. Including Streptomycin, Tyrothricin And Other Antibiotic Therapy 2nd ed. (New York; London: Appleton-Century, 1947 (1945)): 54-56.
46. Jean-Paul Gaudillière and Bernd Gausemeier, 'Molding National Research Systems: the Introduction of Penicillin to Germany and France', Osiris, 20 (2005), 180-202.
47. Patrick Kleedehn, Die Rückkehr auf den Weltmarkt. Die Internationalisierung der Bayer AG Leverkusen nach dem Zweiten Weltkrieg bis zum Jahre 1961 (Stuttgart: Franz Steiner Verlag, 2007), 151-63.
48. Ekkehard Grundmann, Gerhard Domagk-der erste Sieger über die Infektionskrankheiten (Münster: Lit, 2001).
49. Francis Barrymore Smith, The Retreat of Tuberculosis 1850-950 (London: Croom Helm, 1987).
50. V.C. Barry, The Chemotherapy of Tuberculosis (London: Butterworth, 1964).
51. George Weisz and Jesse Olszynko-Gryn, 'The Theory of Epidemiologic Transition: The Origin of a Citation Classic', Journal for the History of Medicine and Allied Sciences, 65, (2009), 287-326.
52. Dietrich Redeker, Zur Entwicklungsgeschichte der Tuberkulostatika und Antituberkulotika (Stuttgart: Deutscher Apotheker Verlag, 1990), 100.
53. Mauro Capocci, ' "A Chain is Gonna Come". Building a Penicillin Production Plant in Post-war Italy', Dynamis, 31, (2011), 343-62
54. Maria Jesús Santemases, 'Screening Antibiotics: Industrial Research by CEPA and Merck in the 1950s', Dynamis, 31, (2011), 407-27.
55. H.W. Florey et al. Antibiotics: A Survey of Penicillin, Streptomycin, and other Antimicrobial Substances from Fungi, Actinomycetes, Bacteria, and Plants (Oxford: Oxford University Press, 1949), 1365-400.
56. H. Dennig and H. Hangleiter, 'Der heutige Stand der Chemotherapie bakterieller Erkrankungen und der Infektionskrankheiten', Deutsche medizinische Wochenschrift, 76, (1951), 647-9
57. Christoph Gradmann, 'Sensitive Matters. The World Health Organisation and Antibiotics Resistance Testing, 1945-75', Social History of Medicine, 26, (2013), 555-74.
58. Kathryn Hillier, 'Babies and Bacteria: Phage Typing, Bacteriologists, and the Birth of Infection Control', Bulletin of the History of Medicine, 80, (2006), 733-61.
59. Arthur Daemmrich, Pharmacopolitics: Drug Regulation in the United States and Germany (Chapel Hill, NC: University of North Carolina Press, 2004), 77-8.
60. Ludwig Heilmeyer, 'Vorläufiger Bericht über Isonikotinsäurehydrazid (Rimifon, Neoteben) auf Grund experimenteller und klinischer Untersuchungen', Deutsche medizinische Wochenschrift, 94, (1952), 1303-8.
61. Ulrike Lindner, Gesundheitspolitik in der Nachkriegszeit: Grossbritannien und die Bundesrepublik Deutschland im Vergleich (München R. Oldenbourg 2004), 127-59.
62. Scott H. Podolsky, 'Antibiotics and the Social History of the Controlled Clinical Trial', Journal for the History of Medicine and Allied Sciences, 65 (2010), 327-67.
63. E.M. Tansey (ed.) Post Penicillin Antibiotics: from Acceptance to Resistance. A Witness Seminar, held at the Wellcome Institute for the History of Medicine, London, 12 May 1998 (London: Wellcome Trust, 2000).
64. Albert Michael Walter, 'Experimentelle Grundlagen und klinische Erfahrungen zur Antibiotika-Resistenz der Bakterien und der Resistenzverzögerung durch eine Kombinationstherapie', Habilitation: University of Freiburg, 1957.
65. Ludwig Heilmeyer and Albert Michael Walter, Antibiotika-Fibel. Indikation und Anwendung der Chemotherapeutika und Antibiotika (Stuttgart: Thieme, 1954).
66. Albert Michael Walter et al., Antibiotika-Fibel. Antibiotika und Chemotherapie (Stuttgart: Thieme, 1969).
67. Jean-Paul Gaudillière and Ulrike Thoms, 'Introduction', in J.-P. Gaudillière and U Thoms (eds), Research for Sales: The Development of Scientific Marketing in the 20th Century Pharmaceutical Industry (London: Pickering and Chatto, forthcoming), 1-17.
68. Ilana Löwy, Between Bench and Bedside: Science, Healing and Interleukin-2 in a Cancer Ward (Cambridge, MA; London: Harvard University Press, 1996)
69. Alberto Cambrosio and Peter Keating, Biomedical Platforms. Realigning the Normal and the Pathological in Late-Twentieth-Century Medicine (Cambridge, MA: MIT Press, 2003), 50.
70. H.G. Lazell, From Pills to Penicillin: The Beecham Story: A Personal Account (London: Heinemann, 1975), 177-9.
71. Flurin Condrau and Robert Kirk, 'Negotiating Hospital Infections: The Debate between Ecological Balance and Eradication Strategies in British Hospitals, 1947-69', Dynamis, 31, (2011), 385-405
72. Jeremy Greene, Prescribing by Numbers: Drugs and the Definition of Disease (Baltimore, MD: Johns Hopkins University Press, 2007).
73. John T. MacFarlane andMichaelWorboys, 'The Changing Management of Acute Bronchitis in Britain, 1940-70: The Impact of Antibiotics', Medical History, 52, (2008), 47-72.
74. Aya Homei and Michael Worboys, Pathologies of Progress: Fungal Disease in Britain and the United States, 1850-2000 (Basingstoke: Palgrave, 2013).
75. Linda Bryder, Flurin Condrau and Michael Worboys, 'Tuberculosis and its histories: then and now', in F Condrau and M Worboys (eds), Tuberculosis Then and Now: Perspectives on the History of an Infectious Disease, (Montreal: McGill-Queens University Press, 2010), 3-23.
76. Charles H. Stuart-Harris and David M. Harris (eds), The Control of Antibiotic-resistant Bacteria, (London; New York: Academic Press, 1982)
77. John Mann, The Elusive Magic Bullet: The search for the Perfect Drug (Oxford: Oxford University Press, 1999)
78. J. Parascandola (ed.) The History of Antibiotics: Symposium, (Madison, WI: American Institute of the History of Pharmacy, 1980).
79. Viviane Quirke and Jean-Paul Gaudillière, 'The Era of Biomedicine: Science, Medicine, and Public Health in Britain and France after the Second World War', Medical History, 52, (2008), 441-52, here 451.
80. Louis Galambos and Jane Eliot Sewell, Networks of Innovation: Vaccine Development at Merck, Sharp and Dohme, and Mulford, 1895-1995 (Cambridge: Cambridge University Press, 1996), 241-3